Page 2 - Ionis Core News Today

First Trust Advisors LP lowered its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 14.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,780,933 shares of the company’s stock after selling 296,327 shares during the period. […]

Tweedy Browne Co LLC raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 30.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,541,136 shares of the company’s stock after buying an additional 818,148 shares during the quarter. Ionis Pharmaceuticals accounts for […]

Arizona State Retirement System boosted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 3.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,047 shares of the company’s stock after acquiring an additional 1,367 shares during the quarter. […]

VNET Group restated their maintains rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) in a research note released on Thursday, Benzinga reports. IONS has been the subject of several other research reports. Citigroup raised Ionis Pharmaceuticals from a sell rating to a neutral rating and raised their price target for the stock from […]

Citigroup upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) from a sell rating to a neutral rating in a research report released on Thursday morning, The Fly reports. The firm currently has $36.00 price objective on the stock, up from their previous price objective of $30.00. A number of other brokerages also recently weighed […]

Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating)‘s stock had its “maintains” rating reaffirmed by investment analysts at VNET Group in a report issued on Thursday, Benzinga reports. Several other equities analysts have also weighed in on the company. SVB Securities cut their target price on Ionis Pharmaceuticals from $34.00 to $27.00 in a report on Thursday, […]

Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) posted its quarterly earnings data on Wednesday. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.13, Briefing.com reports. Ionis Pharmaceuticals had a negative net margin of 45.75% and a negative return on equity of 43.01%. The company had revenue […]

Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 3rd. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Ionis Pharmaceuticals has set its FY 2023 guidance at EPS.Individual interested in participating in the company’s earnings conference call […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has been assigned an average recommendation of “Hold” from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) – Stock analysts at Zacks Research increased their Q1 2023 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 19th. Zacks Research analyst K. Shah now forecasts that the company will earn ($1.00) per share […]